New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia
暂无分享,去创建一个
Y. Pijnenburg | A. Lleó | H. Zetterberg | S. Gandy | C. Onyike | C. Teunissen | F. Oliveira | C. Udeh-Momoh | M. del Campo
[1] N. Mulder,et al. Revealing the Mutational Spectrum in Southern Africans With Amyotrophic Lateral Sclerosis , 2022, Neurology: Genetics.
[2] H. Zetterberg,et al. A high‐performance biomarker panel for Alzheimer’s disease screening and staging identified by large‐scale plasma proteomic profiling , 2021, Alzheimer's & Dementia.
[3] J. Clarimón,et al. Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia , 2021, Translational Neurodegeneration.
[4] Sheng-Yang M. Goh,et al. Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve , 2021, Alzheimer's & Dementia.
[5] K. Blennow,et al. Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[6] R. Vandenberghe,et al. A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study , 2021, Molecular neurodegeneration.
[7] W. Flier,et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation , 2021, The Lancet Neurology.
[8] William T. Hu,et al. Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies , 2021, Biomolecules.
[9] P. Scheltens,et al. A neurologist’s perspective on serum neurofilament light in the memory clinic: a prospective implementation study , 2021, Alzheimer's research & therapy.
[10] G. Bergström,et al. Next generation plasma proteome profiling to monitor health and disease , 2021, Nature Communications.
[11] A. Fagan,et al. African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants , 2021, Neurology: Genetics.
[12] A. Lleó,et al. Race and Alzheimer Disease Biomarkers , 2021, Neurology: Genetics.
[13] Sheng-Yang M. Goh,et al. Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[14] K. Blennow,et al. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology , 2021, Acta Neuropathologica.
[15] N. Mulder,et al. Repeats expansions in ATXN2, NOP56, NIPA1 and ATXN1 are not associated with ALS in Africans , 2021, IBRO neuroscience reports.
[16] J. Glass,et al. Comparison of Phenotypic Characteristics and Prognosis Between Black and White Patients in a Tertiary ALS Clinic , 2020, Neurology.
[17] K. Blennow,et al. Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease , 2020, Neurology.
[18] D. Galimberti,et al. Fluid biomarkers in frontotemporal dementia: past, present and future , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[19] Suzanne E. Schindler,et al. Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework , 2020, Annals of neurology.
[20] K. Blennow,et al. Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias , 2020, Neurology.
[21] Patrick J. Lao,et al. Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study , 2020, medRxiv.
[22] L. Petrucelli,et al. C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy , 2020, Science Translational Medicine.
[23] Michelle K. Cahill,et al. Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency , 2020, Nature.
[24] W. M. van der Flier,et al. Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype , 2020, Neurology.
[25] P. Manganotti,et al. TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients , 2020, Brain communications.
[26] K. Blennow,et al. Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[27] B. Tannous,et al. Blood platelet RNA enables the detection of multiple sclerosis , 2020, Multiple sclerosis journal - experimental, translational and clinical.
[28] K. Kultima,et al. Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers , 2020, Translational Neurodegeneration.
[29] H. Vinters,et al. Expanding the Phenotype of Frontotemporal Lobar Degeneration With FUS-Positive Pathology (FTLD-FUS). , 2020, Journal of neuropathology and experimental neurology.
[30] David T. Jones,et al. Progressive dysexecutive syndrome due to Alzheimer’s disease: a description of 55 cases and comparison to other phenotypes , 2020, Brain communications.
[31] K. Blennow,et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts , 2020, The Lancet Neurology.
[32] C. Jack. The transformative potential of plasma phosphorylated tau , 2020, The Lancet Neurology.
[33] P. Worley,et al. Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[34] Y. Pijnenburg,et al. Frontotemporal Dementia: Correlations Between Psychiatric Symptoms and Pathology , 2020, Annals of neurology.
[35] S. Baez,et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. , 2020, Brain : a journal of neurology.
[36] G. Escaramís,et al. A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid β-amyloid42, total-tau, phospho-tau and α-synuclein in the differential diagnosis of neurodegenerative dementia , 2020, Journal of Neurology.
[37] G. Frisoni,et al. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[38] K. Blennow,et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration , 2020, Nature Medicine.
[39] Bin Zhang,et al. Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression , 2020, Neuron.
[40] B. Boeve,et al. Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[41] C. Duyckaerts,et al. Homozygous GRN mutations: new phenotypes and new insights into pathological and molecular mechanisms. , 2019, Brain : a journal of neurology.
[42] C. Masters,et al. Cerebrospinal fluid neurofilament light chain is elevated in Niemann–Pick type C compared to psychiatric disorders and healthy controls and may be a marker of treatment response , 2019, The Australian and New Zealand journal of psychiatry.
[43] Nick C Fox,et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study , 2019, The Lancet Neurology.
[44] H. Vanderstichele,et al. APP‐derived peptides reflect neurodegeneration in frontotemporal dementia , 2019, Annals of clinical and translational neurology.
[45] O. Hansson,et al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease , 2019, Acta Neuropathologica Communications.
[46] M. DeMarco,et al. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis , 2019, Alzheimer's & dementia.
[47] B. Dickerson,et al. New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures , 2019, Alzheimer's & Dementia.
[48] P. Hartikainen,et al. Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders , 2019, Journal of Neurology.
[49] I. Mackenzie,et al. Subcortical TDP-43 pathology patterns validate cortical FTLD-TDP subtypes and demonstrate unique aspects of C9orf72 mutation cases , 2019, Acta Neuropathologica.
[50] David T. Jones,et al. Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium , 2019, Alzheimer's & Dementia.
[51] C. van Broeckhoven,et al. The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications , 2019, Front. Neurosci..
[52] K. Blennow,et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. , 2019, JAMA neurology.
[53] P. Steinacker,et al. Biomarkers for diseases with TDP-43 pathology , 2019, Molecular and Cellular Neuroscience.
[54] C. Schönfeldt-Lecuona,et al. Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. , 2019, Journal of psychiatric research.
[55] G. Agenbag,et al. C9orf72 repeat expansions in South Africans with amyotrophic lateral sclerosis , 2019, Journal of the Neurological Sciences.
[56] J. Hardy,et al. Genetics and molecular mechanisms of frontotemporal lobar degeneration: an update and future avenues , 2019, Neurobiology of Aging.
[57] M. Sormani,et al. Blood neurofilament light as a potential endpoint in Phase 2 studies in MS , 2019, Annals of clinical and translational neurology.
[58] J. Rohrer,et al. An update on genetic frontotemporal dementia , 2019, Journal of Neurology.
[59] M. Grossman,et al. Clinical Correlates of Alzheimer's Disease Cerebrospinal Fluid Analytes in Primary Progressive Aphasia , 2019, Front. Neurol..
[60] C. Geula,et al. Revisiting the utility of TDP-43 immunoreactive (TDP-43-ir) pathology to classify FTLD-TDP subtypes , 2019, Acta Neuropathologica.
[61] R. Batrla,et al. Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers , 2019, Alzheimer's & dementia.
[62] M. Grossman,et al. Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics , 2019, Annals of clinical and translational neurology.
[63] Nick C Fox,et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease , 2019, Nature Medicine.
[64] D. Stuss,et al. Therapeutic trial design for frontotemporal dementia and related disorders , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[65] J. Trojanowski,et al. Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[66] A. Fagan,et al. Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory , 2018, Annals of clinical and translational neurology.
[67] K. Fliessbach,et al. Serum neurofilament light chain in behavioral variant frontotemporal dementia , 2018, Neurology.
[68] William T. Hu,et al. Novel CSF biomarkers to discriminate FTLD and its pathological subtypes , 2018, Annals of clinical and translational neurology.
[69] K. Blennow,et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease , 2018, Neurology.
[70] for the Alzheimer’s Disease Neuroimaging Initiative,et al. Sex differences in Alzheimer disease — the gateway to precision medicine , 2018, Nature Reviews Neurology.
[71] B. Boeve,et al. Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype , 2018, Acta Neuropathologica.
[72] J. Trojanowski,et al. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes , 2018, JAMA neurology.
[73] C. van Broeckhoven,et al. Genotype–phenotype links in frontotemporal lobar degeneration , 2018, Nature Reviews Neurology.
[74] D. Geschwind,et al. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers , 2018, Annals of clinical and translational neurology.
[75] W. M. van der Flier,et al. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum , 2018, Neurology.
[76] Nick C Fox,et al. Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic , 2018, Alzheimer's Research & Therapy.
[77] C. van Broeckhoven,et al. Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration , 2018 .
[78] K. Blennow,et al. White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation , 2018, Alzheimer's Research & Therapy.
[79] J. Hodges,et al. Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies , 2017, Brain : a journal of neurology.
[80] J. Galvin,et al. The social and economic burden of frontotemporal degeneration , 2017, Neurology.
[81] J. Trojanowski,et al. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration , 2017, Annals of neurology.
[82] J. Molinuevo,et al. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration , 2017, Neurology.
[83] E. Kremmer,et al. Poly‐GP in cerebrospinal fluid links C9orf72‐associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD , 2017, EMBO molecular medicine.
[84] Susan L Cotman,et al. Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis , 2017, Science Translational Medicine.
[85] William T. Hu,et al. Poly(Gp) Proteins Are A Useful Pharmacodynamic Marker For C9Orf72-Associated Amyotrophic Lateral Sclerosis , 2017 .
[86] P. Scheltens,et al. Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders , 2017, Alzheimer's & dementia.
[87] J. Trojanowski,et al. Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration , 2017, Acta Neuropathologica.
[88] Y. Pijnenburg,et al. Progranulin Levels in Plasma and Cerebrospinal Fluid in Granulin Mutation Carriers , 2016, Dementia and Geriatric Cognitive Disorders Extra.
[89] S. Ourselin,et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia , 2016, Annals of clinical and translational neurology.
[90] P. Rabins,et al. Survival in Frontotemporal Dementia Phenotypes: A Meta-Analysis , 2016, Dementia and Geriatric Cognitive Disorders.
[91] Y. Pijnenburg,et al. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics , 2016, Alzheimer's & dementia.
[92] W. M. van der Flier,et al. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes , 2015, Alzheimer's & dementia.
[93] J. Molinuevo,et al. Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria (FTDC) in a clinicopathological cohort , 2015, Neuropathology and applied neurobiology.
[94] M. Weiner,et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. , 2015, Brain : a journal of neurology.
[95] N. Kandiah,et al. Cost Related to Dementia in the Young and the Impact of Etiological Subtype on Cost. , 2015, Journal of Alzheimer's disease : JAD.
[96] M. Blankenstein,et al. Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays , 2015, Front. Neurol..
[97] Serggio C. Lanata,et al. The behavioural variant frontotemporal dementia (bvFTD) syndrome in psychiatry , 2015, Journal of Neurology, Neurosurgery & Psychiatry.
[98] Murray Grossman,et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine , 2015, Acta Neuropathologica.
[99] S. Sorbi,et al. Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia , 2015, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[100] Magda Tsolaki,et al. Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology , 2014, Alzheimer's & Dementia.
[101] S. McKnight,et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells , 2014, Science.
[102] O. Hendrich,et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins , 2014, Science.
[103] P. Thompson,et al. A Systematic Review of Biomarkers for Disease Progression in Alzheimer's Disease , 2014, PloS one.
[104] K. Rankin,et al. Satiety-related hormonal dysregulation in behavioral variant frontotemporal dementia , 2014, Neurology.
[105] L. Grinberg,et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration , 2014, Annals of neurology.
[106] Chadwick M. Hales,et al. Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP , 2013, Neurology.
[107] A. Isaacs,et al. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci , 2013, Acta Neuropathologica.
[108] Kevin F. Bieniek,et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS , 2013, Acta Neuropathologica.
[109] S. Lorenzl,et al. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations , 2013, Acta Neuropathologica.
[110] M. Mesulam. Primary progressive aphasia and the language network , 2013, Neurology.
[111] C. Nilsson,et al. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia , 2013, BMC Neurology.
[112] D. Neary,et al. Sensitivity and specificity of FTDC criteria for behavioral variant frontotemporal dementia , 2013, Neurology.
[113] J. Gilbert,et al. Repeat expansions in the C9ORF72 gene contribute to Alzheimer's disease in Caucasians , 2013, Neurobiology of Aging.
[114] J. Diehl-Schmid,et al. The epidemiology of frontotemporal dementia , 2013, International review of psychiatry.
[115] Mark Hallett,et al. Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.
[116] J. Clarimón,et al. Analysis of the C9orf72 Gene in Patients with Amyotrophic Lateral Sclerosis in Spain and Different Populations Worldwide , 2013, Human mutation.
[117] K. Blennow,et al. Development and assessment of sensitive immuno‐PCR assays for the quantification of cerebrospinal fluid three‐ and four‐repeat tau isoforms in tauopathies , 2012, Journal of neurochemistry.
[118] J. Molinuevo,et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. , 2012, Biomarkers in medicine.
[119] Murray Grossman,et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases , 2012, Acta Neuropathologica.
[120] C. Jack,et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics , 2012, Brain : a journal of neurology.
[121] David Heckerman,et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.
[122] Nick C Fox,et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.
[123] Giovanni B. Frisoni,et al. The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers , 2011, Alzheimer's & Dementia.
[124] J. Trojanowski,et al. A harmonized classification system for FTLD-TDP pathology , 2011, Acta Neuropathologica.
[125] J. Ule,et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. , 2011, Nature neuroscience.
[126] B. Miller,et al. Classification of primary progressive aphasia and its variants , 2011, Neurology.
[127] K. Rankin,et al. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. , 2011, The Journal of clinical psychiatry.
[128] N. Cairns,et al. Distinct pathological subtypes of FTLD-FUS , 2011, Acta Neuropathologica.
[129] Chengjie Xiong,et al. YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease , 2010, Biological Psychiatry.
[130] J. V. van Swieten,et al. Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration , 2009, Journal of Neurology.
[131] John Q. Trojanowski,et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update , 2009, Acta Neuropathologica.
[132] Nick C Fox,et al. The heritability and genetics of frontotemporal lobar degeneration , 2009, Neurology.
[133] H. Kretzschmar,et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. , 2009, Brain : a journal of neurology.
[134] John L. Robinson,et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. , 2009, Archives of neurology.
[135] M. Freedman,et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[136] B. Boeve. Links Between Frontotemporal Lobar Degeneration, Corticobasal Degeneration, Progressive Supranuclear Palsy, and Amyotrophic Lateral Sclerosis , 2007, Alzheimer disease and associated disorders.
[137] Robert H. Brown,et al. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains , 2007, Acta Neuropathologica.
[138] J. Schneider,et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration , 2007, Acta Neuropathologica.
[139] Y. Pijnenburg,et al. CSF neurofilament proteins in the differential diagnosis of dementia , 2007, Journal of Neurology, Neurosurgery & Psychiatry.
[140] S. Melquist,et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. , 2006, Human molecular genetics.
[141] Bruce L. Miller,et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.
[142] S. Melquist,et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17 , 2006, Nature.
[143] Jennifer Farmer,et al. Frontotemporal dementia: Clinicopathological correlations , 2006, Annals of neurology.
[144] P. Lantos,et al. Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration , 2002, Journal of neuropathology and experimental neurology.
[145] Katharina Buerger,et al. Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease , 2001, Annals of neurology.
[146] K. Blennow,et al. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD , 2000, Neurology.
[147] Ronald C. Petersen,et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.
[148] M. Farrer,et al. Localization of frontotemporal dementia with parkinsonism in an Australian kindred to chromosome 17q21–22 , 1997, Annals of neurology.
[149] M. Hallett,et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.
[150] C. Teunissen,et al. Guidelines for CSF Processing and Biobanking: Impact on the Identification and Development of Optimal CSF Protein Biomarkers. , 2019, Methods in molecular biology.
[151] P. Nilsson,et al. Highly multiplexed antibody suspension bead arrays for plasma protein profiling. , 2013, Methods in molecular biology.
[152] J. Pariente,et al. Definite behavioral variant of frontotemporal dementia with C9ORF72 expansions despite positive Alzheimer's disease cerebrospinal fluid biomarkers. , 2012, Journal of Alzheimer's disease : JAD.
[153] A. Vighetto,et al. Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia. , 2011, Journal of Alzheimer's disease : JAD.
[154] E. Buratti,et al. Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. , 2008, Frontiers in bioscience : a journal and virtual library.
[155] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .